Skip to main content
Health Gate Turkey

Breast Cancer

Breast Cancer: Diagnosis, Planning and Follow-Up

Breast cancer is not one disease; stage, histology, grade, ER, PR, and HER2 can change treatment. Care may involve surgery, radiation, hormone therapy, chemotherapy, targeted therapy, immunotherapy, or combinations. Treatment sequencing also matters, especially when therapy begins before surgery.

What Is Breast Cancer, and Why Is It Not One Single Disease?

Breast cancer includes biologically different diseases arising from breast tissue, so one treatment pathway cannot fit every diagnosis. Invasive ductal and invasive lobular cancers have different growth patterns and pathological features. Ductal carcinoma in situ remains confined within breast ducts and differs from invasive cancer. Pathologists also evaluate tumor grade and important biomarkers. These findings help clinicians understand cancer behavior and select appropriate treatment categories. Two tumors of similar size can therefore require different systemic treatments. Treatment planning should combine pathology, anatomical stage, biomarkers, patient health, menopausal status, and individual treatment priorities.

Breast Cancer

Which Tests Help Define a Breast Cancer Treatment Plan?

Breast cancer treatment planning requires pathology, imaging, biomarkers, and selected additional tests rather than diagnosis from imaging alone.

  • Biopsy: Tissue examination confirms cancer type and provides information about invasive or noninvasive disease.

  • ER and PR: Hormone-receptor testing identifies cancers that may respond to endocrine treatment.

  • HER2: HER2 testing helps determine whether HER2-directed treatments may become relevant.

  • Imaging: Mammography, ultrasound, MRI, or staging imaging may define disease extent when clinically indicated.

  • Additional testing: Selected patients may need genomic tumor testing or inherited cancer-risk testing.

Not every patient requires every available test.

How Do Stage, Grade, ER, PR and HER2 Change Breast Cancer Treatment?

Stage and tumor biology change treatment because they describe different aspects of breast cancer behavior and extent. Stage considers the primary tumor, regional lymph nodes, and distant spread. Grade describes how abnormal the cancer appears microscopically and reflects biological aggressiveness. ER and PR identify hormone-receptor biology that can make endocrine therapy relevant. HER2 status can identify tumors suitable for HER2-directed treatment. Triple-negative breast cancer lacks the standard ER, PR, and HER2 targets used in other subtypes. Clinicians therefore interpret anatomical stage alongside biomarkers instead of using tumor size as the only treatment guide.

What Is the Difference Between Genomic Tumor Testing and Hereditary Genetic Testing?

Genomic tumor testing examines cancer biology, while hereditary genetic testing looks for inherited variants carried throughout the body. Multigene tumor assays measure gene activity within breast cancer cells. In selected early cancers, these tests can help estimate recurrence risk and inform systemic treatment decisions. Germline testing usually uses blood, saliva, or another normal-tissue sample. It evaluates inherited variants in genes such as BRCA1, BRCA2, and other cancer-susceptibility genes. Germline results can affect treatment, future cancer-risk management, and relatives. A genomic recurrence test therefore cannot substitute automatically for hereditary cancer testing.

Why Can Treatment Before Breast Cancer Surgery Change the Later Treatment Plan?

Neoadjuvant treatment can change surgery and later therapy because response becomes additional information about the cancer's biology. Treatment before surgery can include chemotherapy, targeted therapy, immunotherapy, or endocrine therapy in appropriate settings. Clinicians document the tumor before treatment so the original disease extent remains known. Surgery then provides tissue showing whether invasive cancer remains. Residual Cancer Burden can quantify remaining cancer within the breast and regional lymph nodes after neoadjuvant chemotherapy. NCI recognizes RCB as a validated prognostic measure. Residual disease can influence postoperative treatment decisions, particularly in HER2-positive and triple-negative disease.

Why Do Some Breast Cancer Patients Need Less Axillary Surgery Than Before?

Some early breast cancer patients can avoid extensive axillary surgery because modern evidence supports more selective lymph-node management. Sentinel lymph node biopsy samples the first draining lymph nodes rather than routinely removing many axillary nodes. A positive sentinel node also does not automatically require complete axillary dissection in every treatment pathway. The 2025 ASCO guideline further supports omitting sentinel biopsy in carefully selected early-stage patients. Decisions depend on tumor characteristics, clinical node findings, imaging, planned breast surgery, radiation, and systemic treatment. Less axillary surgery should follow defined eligibility rather than a general preference for smaller procedures.

What Changes When Breast Cancer Becomes Metastatic?

Metastatic breast cancer requires systemic disease management because cancer has spread beyond the breast and regional lymph nodes. Current treatment aims to prolong life, control disease, relieve symptoms, and maintain quality of life. Treatment selection still depends heavily on tumor biology. Hormone receptors, HER2 expression, previous treatments, molecular findings, organ involvement, symptoms, and patient health can influence therapy. Biomarkers can also change during the disease course, making repeat testing relevant in selected patients. Surgery and radiation can still have specific roles, particularly for symptoms or selected local problems, but systemic therapy usually drives overall management.

What Should International Patients Verify Before Breast Cancer Care in Turkey?

International patients should verify regulatory status, pathology, multidisciplinary planning, and continuing care before arranging breast cancer treatment in Turkey.

  • Check the Ministry of Health's current list of providers authorized for international health-tourism services.

  • Provide biopsy slides, pathology reports, ER, PR, HER2 results, and original imaging files when available.

  • Clarify whether treatment starts with surgery or systemic therapy and how postoperative pathology will affect later decisions.

  • Arrange medical oncology, surgery, radiation oncology, genetic counseling, and rehabilitation follow-up when clinically relevant.

  • Confirm how records, pathology specimens, prescriptions, and urgent treatment information will transfer after returning home.

Authorization confirms regulatory status but does not guarantee treatment suitability or clinical outcomes.

This content provides general medical information and does not recommend a specific breast cancer treatment, healthcare provider, or clinical outcome.

Last updated: August 14, 2026

Sources

  • https://www.cancer.gov/types/breast/diagnosis

  • https://www.cancer.gov/types/breast/treatment

  • https://www.cancer.gov/types/breast/hp/breast-treatment-pdq

  • https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet

  • https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet

  • https://ascopubs.org/doi/10.1200/JCO-25-00099

  • https://saglikturizmi.saglik.gov.tr/EN,69063/healthcare-providers-authorized-by-the-ministry.html

  • https://shgmturizmdb.saglik.gov.tr/EN-108974/regulation-on-international-health-tourism-and-tourist-health.html

  • https://antalyaism.saglik.gov.tr/TR-366500/saglik-hizmetlerinde-tanitim-ve-bilgilendirme--faaliyetleri-hakkinda-yonetmelik.html